|
|
Article: ViroPharma told Vanocin not focus of OGD meeting by FDA.(Brief article)
- Article from:
- Pharma Marketletter
- Article date:
- July 14, 2008
CopyrightCOPYRIGHT 2008 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Pennsylvania, USA-based ViroPharma has been informed by the US Food and Drug Administration that the July 23 meeting of its Advisory Committee for Pharmaceutical Science and Clinical Pharmacology is not intended to discuss specifically ViroPharma's Vancocin (vancomycin hydrochloride capsules) or any other drug products.
The FDA has informed the US firm that the Office of Generic Drugs will only present for the Committee's consideration issues of general applicability to all locally-acting drugs that treat gastrointestinal ...